Psychedelic-assisted therapies could hit UK markets sooner than expected – and sooner than may happen in Europe – under a new government funding plan for innovative...
In response to a letter from a group of cross-party MEPs calling for the EU to act fast on psychedelics, the European Medicines Agency will be...
PharmAla Biotech Holdings has been named the exclusive supplier of both GMP and engineering MDMA to Awakn LS Europe Holdings Limited.
Over 100 academics, psychologists, anthropologists and activists have signed a manifesto launched by the Chacruna Institute for Psychedelic Plant Medicines calling for an end to police...
Awakn Life Sciences has signed its first Licensing Partnership agreement in Europe with a healthcare consortium.
In two letters seen by Psychedelic Health, a cross-party group of MEPs has expressed concern over the lack of progress with the medical use of psychedelics...
Awakn Life Sciences has announced that Awakn Clinics Trondheim is now open and that it has initiated a feasibility study of MDMA leveraging Catalent’s proprietary Zydis...
In what marks an important development for Europe, a number of EU bodies have published a joint commentary in the world-leading medical journal, The Lancet, acknowledging...
Tadeusz Hawrot, Founder and Executive Director of the Psychedelic Access and Research European Alliance (PAREA), speaks to Psychedelic Health about how the organisation plans to campaign...
The first patient has been dosed in Small Pharma’s Phase I study that is comparing the profiles of the company’s proprietary formulation of DMT.
